Life sciences VC Apple Tree Partners has launched its first U.K.-based portfolio company, providing $53 million in series A funding for immunology specialist Adendra Therapeutics Ltd.

Australian researchers have discovered a key differentiation process that provides an essential immune function in helping to control cancer and infectious diseases.